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terventions (pharmacologic and non-pharmacologic), 6) types of 
outcome measures (self-reported, performance-based, examina- 
tion, imaging), and 7) considerations in the statistical analysis of 
data. Participants will complete an exercise that designs a clinical 
trial for symptom and structure modification in patients with knee 
osteoarthritis. 
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ROLE OF MATRIX METALLOPROTEINASES IN 
CARTILAGE AND BONE DURING SKELETAL 
REMODELING 
Stephen M Krane 
Matrix metalloproteinases (MMPs) are expressed in cartilage dur- 
ing embryonic development and later during remodeling. Mmp9, 
although not a collagenase is expressed early in embryogen- 
esis during endochondral ossification and Mmp9 deficiency in 
mice results in abnormalities that affects growth plates. Mmp13 
(collagenase-3), a highly expressed collagenolytic MMP in carti- 
lage and in developing and remodeling bone, also has a role in 
the joint tissue destruction that is a major feature of various forms 
of human arthritis. We have targeted a null mutation in mouse 
Mmp13 that resulted in a profound embryonic and adult skeletal 
phenotype characterized by abnormal growth plates and delayed 
ossification. During embryonic development at the earliest stage 
examined, Mmp13 -/- mice had growth plates in long bones al- 
most double in length, accounted for by increases in the zone of 
hypertrophy. Mmp13, produced by chondrocytes but not by os- 
teoclasts/chondroclasts, i  particularly effective in proteolysis of 
type II compared to type I collagen. Using antibodies that detect 
epitopes in the specific proteolytic fragments, we obtained evi- 
dence for Mmp13 cleavage of type II collagen in vivo in wt mice, 
but not in Mmp13-/-mice. It is thus unlikely that other Mmps com- 
pensate for the loss of Mmp13 function in cartilage. The delay 
in ossification, so prominent in 15.5 dpc Mmp13 -/- embryos, is 
largely transient and older Mmp13 -/- mice have increased bone 
deposition. Mmp8 is also expressed in newborn Mmp13 -/- and wt 
skeletons but Mmp '-/- mice have normal skeletons. Type X colla- 
gen is also a substrate for MMP1 and Mmp13. The area of type X 
collagen deposition was significantly increased in growth plates 
from Mmp13-/-mice, consistent with decreased proteolysis. In- 
creased synthesis of type X collagen could also contribute. Based 
on our results, Mmp13 has a critical role in regulating events in 
the growth plate beginning in embryonic development. Deficiency 
of Mmpl 3 with failure to normally resorb collagens in the cartilage 
ECM profoundly affects cellular activities that underlie differenti- 
ation of hypertrophic hondrocytes that persist in newborn and 
adult mice. The phenotype of / adult Mmp13--mice with increased 
length of growth plates, increased numbers of chondrocytes and 
distortion of alignment of the rows of chondrocytes thus has fea- 
tures of a chondrodysplasia. Articular cartilage is also affected. 
It is pertinent hat a form of human chondrodysplasia, the Mis- 
souri variant of spondyloepimetaphyseal dysplasia is caused by a 
mutation in MMP13 that results in misfolding, intracellular degra- 
dation and MMP13 deficiency. Human mutations in MMP2 also 
result in a skeletal phenotype (nodulosis, osteolysis and arthropa- 
thy) distinct from that in MMP13 mutations. Bone is abnormal in 
Mmp2-null mice but the mice do not show other features of the 
human mutation. 
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INTEGRIN-SYNDECAN CO-OPERATION GOVERNS THE 
ASSEMBLY OF SIGNALLING COMPLEXES DURING CELL 
MIGRATION 
Martin J Humphries 
Cell adhesion receptors play a fundamental role in integrating the 
extracellular matrix with cell signalling complexes, and thereby 
control diverse, distal events in metazoa such as cell fate and 
tissue structure. Within cells, adhesion signalling occurs at focal 
sites and involves the formation and maturation of discrete ad- 
hesion complexes. The sequential modulation of Rho family GT- 
Pase activity is a critical control point determining the efficacy 
of adhesion signalling. Adhesive responses to the extracellular 
matrix protein, fibronectin (FN), which are mediated by members 
of the integrin and syndecan adhesion receptor families, have 
served as a prototype for many of these studies, and the out- 
comes are generally applicable to a large majority of adhesive re- 
sponses. Interestingly, cells plated onto a FN fragment hat binds 
the integrin ~51~1 are able to spread but fail to form adhesion com- 
plexes or fully organise actin into bundled stress fibres unless co- 
stimulated with a distinct FN fragment hat binds syndecan-4. En- 
gagement of syndecan-4 in such pre-spread cells recapitulates 
the Rho family activation profiles observed during spreading on 
whole FN. We have found that adhesion to a ligand of ~51~1 alone 
does not activate one member of the Rho family, Racl, indicating 
that engagement of syndecan-4 is an absolute requirement for 
this key signalling event. In related work, we have examined iffer- 
ences in the mechanism of adhesion complex formation mediated 
by different FN-binding integrins, ~41~1 and ~51~1. Two signalling 
differences were found. First, while ~51~1 required a proteoglycan 
co-receptor (syndecan-4), ~41~1 did not. Second, adhesion con- 
tact formation via ~51~1 required PKC~ activation, but only basal 
PKC~ activity was observed following adhesion via ~41~1. These 
findings demonstrate that different integrins can signal to induce 
focal adhesion formation and migration by different mechanisms, 
and provide insights into the ways that the extracellular environ- 
ment controls cell morphology and movement. 
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NOVEL GENETIC MARKERS OF OSTEOARTHRITIS 
John Loughlin 
Early cross-sectional and longitudinal studies demonstrated fa- 
milial clustering of primary osteoarthritis, implying a genetic com- 
ponent to the disease. However, such clustering could also be the 
result of shared environmental factors within a family. Twin studies 
have since been performed that demonstrate a clear heritability to 
OA at a number of skeletal sites, including hands, hips, knees and 
the spine [1]. Other epidemiological studies have also been per- 
formed investigating the nature of OA transmittance from parents 
to offspring and the prevalence of disease between relative-pairs, 
particularly siblings. These studies have confirmed a major ge- 
netic component o OA, which is transmitted in a non-Mendelian, 
complex manner. It has gradually become apparent hat the na- 
ture of the genetic risk is likely to vary somewhat between differ- 
ent skeletal sites and may also vary between the sexes, although 
this latter observation is based on a small number of studies and 
needs further investigation to confirm it's veracity. 
With a genetic component established the next step was a hunt 
for the risk alleles. Investigators initially focussed on genes en- 
coding the major structural components of the cartilage extracel- 
lular matrix, such as aggrecan and type II collagen. These stud- 
ies did not provide the expected breakthroughs and prompted a 
re-think on the nature of OA susceptibility: instead of the carti- 
lage matrix being poorly constructed could the susceptibility be 
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acting in those pathways and processes that develop the car- 
tilage and then help maintain the tissue throughout life? Sub- 
sequent genome-wide linkage and association studies have re- 
vealed genes whose proteins do regulate cartilage development 
and homeostasis. Three particularly compelling results are: 1) 
an association to the secreted frizzled-related protein 3 (SFRP3) 
gene FRZB on chromosome 2q32.1 in a UK population [2], 
2) an association to the asporin gene ASPN on chromosome 
9q22.31 in a Japanese population [3] and 3) an association to 
the calmodulin 1 gene CALM1 on chromosome 14q32.11, also in 
a Japanese population [4]. SFRP3, asporin and calmodulin 1 all 
regulate chondrogenesis and help to maintain the cartilage ma- 
trix. However, they do this through distinct pathways: SFRP3 acts 
as an antagonist of extracellular Wnt ligands; asporin influences 
TGF-I~-mediated signalling; calmodulin 1 influences intracellular 
calcium signalling. 
These recent genetic findings suggest that OA genetic risk is act- 
ing on chondrocyte differentiation, proliferation and the general 
homeostatic balance of the articular cartilage ECM rather than 
through an inadequately constructed cartilage ECM. This is an 
important observation since signalling pathways are modifiable. 
The new genetics has therefore identified targets for new drug 
development as well as loci that can now be genotyped to iden- 
tify at-risk individuals for more focussed clinical trials. 
In this talk I shall bring the listener up-to-date with the recent 
breakthroughs and offer a sober assessment of the position of 
the field and what steps need to be taken to ensure these break- 
throughs are exploited for patient benefit. 
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IMAGING IN OSTEOARTHRITIS: TRANSLATIONAL 
RESEARCH APPLICATIONS OF FUNCTIONAL 
CARTILAGE MRI 
Timothy J. Mosher 
Purpose: To review functional techniques for MRI of articular car- 
tilage and present results of recent studies on in viva biomechan- 
ics 
Description: The ability to non-invasively image articular carti- 
lage makes MRI a valuable tool in the study of osteoarthritis. 
Of particular promise are translational research applications that 
bridge basic science studies in animals or tissue samples with 
clinical studies in humans. Given the central role of joint biome- 
chanics in the pathogenesis of OA and difficulty replicating hu- 
man joint biomechanics with animal models, there is growing in- 
terest in developing MRI techniques that are sensitive to changes 
in cartilage when placed under physiologic loads. This presenta- 
tion will review new functional cartilage MRI techniques that have 
been applied to in viva study of human cartilage biomechanics, 
including quantitative cartilage morphometry, delayed gadolinium 
enhanced MRI of Cartilage (DGEMRIC), and cartilage T2 map- 
ping. Recent results demonstrate regional response of cartilage 
to load bearing exercise with greater compressibility near the ar- 
ticular surface. Results obtained from MRI will be compared with 
current understanding of cartilage biomechanics derived from ex 
vivo testing. 
Conclusion: Current MRI techniques demonstrate sensitivity to 
changes in cartilage morphology and biochemical content that 
occur in response to physiological oading conditions. These 
techniques provide new translational research opportunities for 
evaluating the role of altered biomechanics in the pathogenesis 
of OA. 
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EVALUATING PAIN IN OSTEOARTHRITIS 
Maxime Dougados 
The collection of variables such as the level of pain in os- 
teoarthritic (OA) patients might have different purposes but the 
most important is to facilitate a therapeutical decision. 
For this purpose (to make a therapeutical decision), the following 
points have to be considered: 
1. Which pain? 
Pain might be related to the activity (inflammation) or the sever- 
ity (structural damage) or both. Pain occurring during the sec- 
ond part of the night is considered as reflecting an inflammatory 
process. At variance, pain, occurring after physical activities, is 
considered as reflecting a structural damage. Therefore, it is rec- 
ommended to collect separately these two variables. 
2. Pain of the target pain or of the OA patient? 
Localized OA is quite rare. Therefore, even in case of the evalua- 
tion of a single ("target") joint, it is sometimes difficult o differenti- 
ate pain related to this "target" joint to the one related to other OA 
affected joints. For clinical trials, FDA (Food and Drugs Adminis- 
tration) has recommended to use 2~variables: one evaluating the 
"target" joint and another one evaluating the "other OA" joints. 
3. Which anatomical lesion is responsible of pain? 
Pain might be related to an "articular" anatomical esion (carti- 
lage, sub-chondral bone, synovial membrane) but also to peri- 
articular lesion such as tendinitis. 
4. Clinical trials versus daily practice 
During clinical trials, the systematic use of specific tools such as 
VAS Visual Analogue Scale or NRS (Numerical Rating Scale) has 
been fully validated. The use of such tools (instead of the con- 
ventional "how are you doing") has not proven its utility in daily 
practice. 
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OBESITY AND OSTEOARTHRITIS 
Michele M Hooper 
Obesity (BMI _> 30 kg/m 2) is increasing worldwide. In the United 
States, 28% of adult men and 34% of women are obese. There 
is a high prevalence of painful musculoskeletal symptoms in up- 
per and lower extremities in the obese that improve with weight 
loss, including physical function and quality of life. There is a 
modest association between obesity and hand, hip and patello- 
femoral OA but a very strong association with (tibio-femoral) knee 
OA (kOA). Risk ratios for radiographic kOA increase with weight, 
even in normal BMI range and weight loss protects against kOA 
development. Mechanisms of the effect of BMI on kOA include; 
metabolic abnormalities, genetics, malalignment (varus/valgus), 
laxity, meniscectomy, ACL tears, bone density, muscle mass and 
gait biomechanics. Obesity and kOA have moderate degrees of 
heritability, but not through shared genes. Female gender and 
aging are associated with increased fat mass, decreased mus- 
cle mass and increased kOA. Bone density is higher in obesity; 
